載入...
Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?
Although there have been significant insights into the biology of diffuse large B-cell lymphoma (DLBCL) over recent years, progress in our therapeutic approach has been disappointing over the same timeframe. This is not for want of trying. In 2017, R-CHOP (rituximab plus cyclophosphamide, doxorubici...
Na minha lista:
| 發表在: | Hematology Am Soc Hematol Educ Program |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society of Hematology
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6142538/ https://ncbi.nlm.nih.gov/pubmed/29222268 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|